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Summary We have found that elevation of preoperative serum sialyl-Tn antigen (STN) levels is associated
with a poor prognosis for gastric cancer patients, and these high levels remain in the advanced stage of the
disease. We have now examined findings with the combined assay of STN and carcinoembryonic antigen
(CEA) levels with regard to prediction of the prognosis of gastric cancer patients. Serum CEA levels and STN
levels were determined preoperatively in 349 Japanese patients with gastric cancer. The patients were divided
into four groups: (A) the CEA (-) STN (-) group (CEA < 5 ng ml1 ', STN <45 U ml-', n = 286); (B) the
CEA (-) STN (+) group (CEASngml-', STN>45Uml-', n=31); (C) the CEA (+) STN (-) group
(CEA>5ngml-', STN<45Uml-', n=17); and (D) the CEA (+) STN (+) group (CEA>5ngml-',
STN>45 U ml'- , n = 15). Clinicopathological features and the prognosis of these groups were examined. The
distribution of two markers showed no significant correlation. The patients in the CEA (+) STN (+) group
(group D) had more advanced disease than the patients in CEA (-) STN (-) group (group A); tumour size
was larger, serosal invasion was prominent, lymphatic and vascular involvement was frequent and the tumour
was more infiltrative. Lymph node metastasis and hepatic metastasis were more common. Total gastrectomy
was usually performed, and the non-curative rate was higher. The 5-year survival of patients in the CEA (+)
STN (+) (group D) was 14.5 ± 9.5%, that is lower than that of patients in any other group [CEA (+) STN
(-) (group C) 44.1 ± 12.7% (P<0.05); CEA (-) STN (+) (group B) 60.1 ± 9.5% (P>0.05); CEA (-) STN
(-) (group A) 77.6 ± 9.5% (P<0.05)]. This combined assay of these markers will aid in estimating the
prognosis and selecting appropriate drugs and care for gastric cancer patients.
Carcinoembryonic antigen (CEA) is a useful marker to
monitor patients, to evaluate tumour staging in patients with
gastric cancer (Tamada et al., 1982, 1985; Kano et al., 1987)
and to predict prognosis (Maehara et al., 1990). Ten to
twenty percent of CEA-positive Japanese patients had gastric
cancer (Koga et al., 1987; Shimizu et al., 1987). The com-
bination of two different tumour markers is more helpful in
diagnosis than a single determination. Quentmeier et al.
(1987) reported the usefulness of the simultaneous measure-
ment of carbohydrate antigen 12-5 (CA12-5), CEA and car-
bohydrate antigen 19-9 (CA19-9) for gastric cancer and colon
cancer patients. They stated that simultaneous determination
of the three markers led to a more precise assessment of the
outcome for these patients, that is 17.1% (CEA alone) to
34.5% (three determinations) (Quentmeier et al., 1987).
We have now used serum sialyl-Tn antigen (STN) in com-
bination with CEA for assay. STN is an abnormal glyco-
protein, detected using monoclonal antibody TKH-2
(Kjeldsen et al., 1988) and specific to cancer tissue. STN is
expressed in colon cancer cells but not in normal colon cells
(Itzkowitz et al., 1989). In gastric cancer tissue, STN is
expressed specifically in malignant cells (Maeda et al., 1992;
Yamada et al., 1992). In previous work, we examined
preoperative serum STN levels in gastric cancer patients and
its value as a tumour marker for gastric cancer was apparent.
Patients with high serum STN levels have more advanced
gastric cancer and their prognosis is poorer than patients
with lower STN levels (Takahashi et al., 1993).
In the present work, we examined the usefulness of the
combined assay of CEA and STN in patients with gastric
cancer.
Patients and methods
From April 1981 to April 1986, 349 primary gastric cancer
patients were surgically treated in the Department of Surgery
II, Faculty of Medicine, Kyushu University, and National
Kyushu Cancer Center, Fukuoka, Japan. Serum STN and
CEA levels were determined in all these patients. For each
patient, there was no evidence of any other malignancy and
no history of preoperative treatment with anti-cancer drugs.
The pathological diagnoses and classifications were carried
out according to the General Rule for the Gastric Cancer
Study in Surgery and Pathology in Japan (Japanese Research
Society for Gastric Cancer, 1981).
Serum STN levels were measured using a one-step
radioimmunoassay kit (S-Tn Otsuka; Otsuka Assay
Laboratories, Tokushima, Japan) (Imura et al., 1989). This
kit employs competitive binding to the radiolabelled mono-
clonal antibody TKH-2 between serum STN and STN-coated
beads (an immunoradiometric competitive inhibition assay)
(Kjeldsen et al., 1988). Venous blood samples were
immediately separated by centrifugation and placed in liquid
nitrogen. The cut-off value between normal and elevated
STN titres was set to 45 U ml-'. This cut-off value,
45 U ml- 1, is the mean plus one standard deviation of
findings in normal volunteers (Imura et al., 1989). Serum
CEA levels were determined by the double-antibody method
(Maehara et al., 1990). Differentiation between normal and
elevated CEA titres was based on 5.0 ng ml-' as the upper-
most normal concentration. We classified the patients into
four groups according to these cut-off values: (A) low CEA
and low STN levels [CEA (-) STN (-)], (B) low CEA and
high STN levels [CEA (-) STN (+)], (C) high CEA and low
STN levels [CEA (+) STN (-)] and (D) high CEA and high
STN levels [CEA (+) STN (+)].
Clinicopathological data were stored in an IBM (Armonk,
NY, USA) 4381 mainframe computer. The Biomedical Com-
puter Program (BMDP Statistical Package Program, Los
Angeles, CA, USA) was used for all statistical analyses
(Dixon, 1988). Data were analysed using the chi-square and
Mann-Whitney U-tests. For these analyses, the BMDP P4F
and P3f programs were used. Survival curves were calculated
by the Kaplan-Meier method, using the BMDP PIL pro-
gram. Comparisons among the four groups were made using
the generalised Wilcoxon test to analyse equality of the sur-
vival curves. A P-value of less than 0.05 was considered to be
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statistically significant. In the statistical analysis, deaths due
to causes other than gastric carcinoma were considered cen-
sored cases. Unknown data were also excluded from statis-
tical analysis.
Results
Positive rate ofboth CEA and STN, and correlation ofthese
markers
The positive rate of these parameters in case of CEA assay
alone was 9.2% (32/349), while that of STN alone was 13.2%
(46/349). The positive rate for patients either CEA (+) or
STN (+) was 18.1% (63/349). Figure 1 shows the distribu-
tion of CEA and STN levels of 349 patients; there was no
correlation between the two markers (r = 0.023).
Clinicopathologicalfactors
The clinicopathological data on the 349 patients are given in
Table I. The CEA (+) STN (+) group (group D) differs
significantly from the CEA (-) STN (-) group (group A) in
the following variables: age (P<0.05), maximum diameter
(P<0.01), stage (P<0.01), serosal invasion (P<0.01), lym-
phatic involvement (P<0.05), vascular involvement
(P<0.01), histological growth pattern (P<0.05), lymph
node metastasis (P<0.01), hepatic metastasis (P<0.01),
gastric resection (P<0.05), lymph node dissection (P<0.01)
and curability (P<0.01). The CEA (+) STN (+) group
(group D) also differed significantly from the CEA (-) STN
(+) group (group B) in age (P<0.05), maximum diameter
(P<0.05), stage (P<0.05), lymphatic involvement (P<0.05)
and curability (P<0.01). Group D and Group C [CEA (+)
STN (-)] differed in age (P<0.01), maximum diameter
(P<0.01) and stage (P <0.05). Patients who were CEA (+)
STN (+) (group D) had more advanced cancer than patients
in other groups. Sex, tumour location, histology and
peritoneal dissemination were not significantly different
between the four groups.
Survival rates
No patient was lost to follow-up. The mean follow-up time
± s.d. at the time of analysis (November 1991) was
6.07 ± 0.92 years for the 208 survivors of the total 349
patients. The post-operative survival curve among the groups
was also compared (Figure 2). The 5-year survival for
patients with CEA (+) STN (+) (group D) was 14.5 ± 9.5%,
while that of patients in other groups was 44.1 ± 12.7% for
the CEA (+) STN (-) group (group C) (P<0.05),
60.1 ± 9.5% for the CEA (-) STN (+) group (group B)
(P<0.05) and 77.6 ± 9.5% for the CEA (-) STN (-) group
(group A) (P<0.05).
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Figure 1 Distribution of CEA and STN levels of 349 patients.
There was no correlation between preoperative CEA and STN
levels (r = 0.023).
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Figure 2 Survival curves for the four groups. CEA (+) was
defined as a level over 5 ng ml-'. STN (+) was defined as over
45 Umlh'. There was a significant difference in survival time
between patients in the CEA (+) STN (+) and CEA (+) STN
(-) group (groups D and C), CEA (+) STN(+) and CEA (-)
STN(+) groups (groups D and B) and CEA(+)STN (+) and
CEA (-)STN (-) groups (groups D and A) (P<0.05).
Discussion
Changes in surface membrane glycoproteins are common
phenomena in cancer cells (Springer, 1984). Itzkowitz et al.
(1989, 1990) reported that the rate of expression of STN is
low in normal colon mucosa, and that expression of STN is
an independent prognostic factor for colon cancer patients.
STN is little expressed in the normal stomach mucosa, yet it
is expressed in 47.8-54.1% of cancer cells (Maeda et al.,
1992; Yamada et al., 1992). Thus, STN is specifically related
to a cancer state and the serum STN level is considered to be
closely related to a progressive state of the cancer. We have
noted that gastric cancer patients with high preoperative
STN levels tend to have an advanced malignant lesion and
that the prognosis of this group is less satisfactory than that
of the low-STN group (Takahashi et al., 1993).
CEA is also a useful marker for monitoring patients with
gastrointestinal malignancies, and to predict recurrences
(Tamada et al., 1982, 1985; Kano et al., 1987; Maehara et al.,
1990). Prevalence of CEA positivity increases as the disease
progresses (Shimizu et al., 1987). However, biochemically
and immunologically, there is a substantial difference
between CEA and STN. CEA is a high molecular weight
glycoprotein with the immunodeterminant located on the
protein portion of the molecule (Gold et al., 1965), whereas
STN is a highly glycosylated, mucin-like glycoprotein cir-
culating in the serum of cancer patients, and the immuno-
determinant is a sialylated form of glycoprotein containing
N-acetylgalactose connected by O-glycosidic linkages to
serine or threonine residues in the protein backbone (Kjeld-
sen et al., 1988). The immunodeterminant of the former is a
protein antigen that is directly encoded by a specific antigen,
whereas that of the latter is the carbohydrate side chain of
the molecule, which is synthesised by gene-encoded glycosyl-
transferase enzyme, which adds sugars in a sequential man-
ner (Itzkowitz & Kim, 1986; Kjeldsen et al., 1988). As shown
in Figure 1, the distribution of these two markers is not
correlated, thus there may be some difference between
tumours in patients with high CEA levels and those with
high STN levels. Accordingly we separated our patients into
four groups - CEA (+) STN (+) (group D), CEA (-) STN
(+) (group B), CEA (+) STN (-) (group C) and CEA (-)
STN (-) (group A) - so as to obtain a more precise assess-
ment of the prognosis.
As residual or occult tumour cells in gastric cancer may
grow rapidly in the post-operative period, any delay in inges-
tion of anti-cancer drugs reduces the potential for controlling
residual tumours (Schabel, 1975; Gunduz et al., 1979). We
made a multivariate analysis concerning curability, liver
:
.
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Table I Clinicopathological characteristics of gastric cancer patients determined by the levels ofpreoperative serum CEA and STN levels
(A) (B) (C) (D)
CEA <5a CEA <Sa CEA>5a CEA>5a
STN<5b STN>5b STN<5b STN>5b Significancec
Variable (n = 286) (n = 31) (n = 17) (n = 15) (A)(D) (B)(D) (C)(D)
Age 59.6±2.0d 67.8±9.Od 68.1±7.4d 61.6±8.8d P<0.05 P<0.05 P<0.01
Maximum diameter
5.3±3.8d 7.1±3.8d 6.2±1.9d 9.7±3.5d P<O0.01 P<0.05 P<0.01
Stage P<0.01 P<0.05 P<0.05
I 151 9 2 0
II 28 2 4 1
III 57 9 4 3
IV 50 11 7 11
Serosal invasion P<0.01 NS NS
Negative 194 13 7 4
Positive 92 18 10 11
Lymphatic involvement P<0.05 P<0.05 NS
Negative 106 7 1 0
Positive 179 24 16 15
Unknowne 1 0 0 0
Vascular involvement P<0.01 NS NS
Negative 185 11 5 2
Positive 98 20 12 13
Unknowne 3 0 0 0
Histological growth pattern P<0.05 NS NS
Expansive 129 9 2 2
Intermediate 105 11 12 6
Infiltrative 49 11 3 7
Unknowne 3 0 0 0
Lymph node metastasis P<0.01 NS NS
Negative 167 9 2 0
Positive 119 22 15 15
Hepatic metastasis P<0.01 NS NS
Negative 277 28 13 11
Positive 9 3 4 4
Gastric resection P<0.05 NS NS
Partial 215 23 12 7
Total 71 8 5 8
Lymph node dissection' P<0.01 NS NS
RO, R1 42 5 6 90
R2, R3 244 26 11 6
Curability P<0.01 P<0.01 NS
Curative 240 25 9 4
Non-curative 45 6 8 11
Unknowne I 0 0 0
"ng ml ';bU ml- ;cBased onMann-Whitney U-testorchi-squaretest."Mean± standard deviation (s.d.).eUnknowndataandlocalresectionwere
excluded in the comparative analysis. 'According to the General Rules for the Gastric Cancer Study in Surgery and Pathology in Japan. RO, gastric
resection, including the incomplete removal ofgroup I nodes; RI, gastric resection, including the complete removal ofgroup I lymph nodes; R2,
gastric resection, including thecomplete removal ofgroups 1 and 2lymphnodes; R3, gastric resection, includingthecomplete removalofgroups 1, 2
and 3 lymph nodes. NS, not significant.
metastasis, serosal invasion, lymph node metastasis and
peritoneal dissemination, and found evidence for independent
prognostic factors in gastric cancer patients (Maehara et al.,
1991a,b). Whilst these factors can be defined at the time of
surgery, CEA and STN levels can be determined simply and
rapidly prior to the operation.
We conclude that the combined CEA and STN assay is
useful for determining the outcome in patients with gastric
cancer. Intensive chemotherapy and close follow-up are
recommended for such patients.
This work was supported in part by a Grant-in-Aid from the Uehara
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